BiotechTube

Tideglusib

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Myotonic Dystrophy 1

Conditions

Myotonic Dystrophy 1

Trial Timeline

Jul 20, 2016 → Jan 1, 2018

NCT ID
NCT02858908

About Tideglusib

Tideglusib is a phase 2 stage product being developed by AMO Pharma for Myotonic Dystrophy 1. The current trial status is completed. This product is registered under clinical trial identifier NCT02858908. Target conditions include Myotonic Dystrophy 1.

What happened to similar drugs?

0 of 2 similar drugs in Myotonic Dystrophy 1 were approved

Approved (0) Terminated (0) Active (2)
🔄Del-desiran (AOC 1001)Avidity BiosciencesPhase 3
🔄DYNE-101 + PlaceboDyne TherapeuticsPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT07119775Pre-clinicalActive
NCT05004129Phase 2/3Recruiting
NCT02858908Phase 2Completed

Competing Products

16 competing products in Myotonic Dystrophy 1

See all competitors
ProductCompanyStageHype Score
TideglusibAMO PharmaPre-clinical
20
Tideglusib + PlaceboAMO PharmaPhase 2/3
28
TideglusibAMO PharmaPhase 2/3
35
VX-670Vertex PharmaceuticalsPhase 2
42
VX-670 + PlaceboVertex PharmaceuticalsPhase 1/2
39
SAR446268SanofiPhase 1/2
39
rhIGF-I/rhIGFBP-3 + placeboInsmedPhase 2
32
IONIS-DMPKRx + PlaceboIonis PharmaceuticalsPhase 1/2
29
Del-desiran (AOC 1001)Avidity BiosciencesPhase 3
44
ARO-DM1 Intravenous (IV) Infusion + Placebo Intravenous (IV) Infusion + ARO-DM1 subcutaneous (SC) injection + Placebo Subcutaneous (SC) InjectionArrowhead PharmaceuticalsPhase 1/2
36
DYNE-101 + PlaceboDyne TherapeuticsPhase 3
41
DYNE-101 + PlaceboDyne TherapeuticsPhase 1/2
33
Pitolisant Oral Tablet + Placebo oral tabletHarmony BiosciencesPhase 2
29
PGN-EDODM1PepGenPhase 2
32
PGN-EDODM1PepGenPhase 2
32
PGN-EDODM1 for infusionPepGenPhase 1
19